GeoVax Labs, Inc. (GOVX-NASDAQ)

GeoVax Labs, Inc. is a clinical-stage biotechnology company advancing next-generation vaccines and immunotherapies for some of the world’s most serious infectious diseases and solid tumor cancers. The Company’s lead infectious disease candidate, GEO-CM04S1, is a novel COVID-19 vaccine designed to offer broader and more durable protection. GEO-CM04S1 is currently being evaluated in three Phase 2 clinical trials and is the focus of a BARDA-funded Phase 2b trial involving 10,000 participants, comparing its efficacy to an approved COVID-19 vaccine. The ongoing studies target immunocompromised individuals, such as those with hematologic cancers, patients with chronic lymphocytic leukemia (CLL), and healthy individuals previously vaccinated with mRNA-based vaccines. In oncology, GeoVax’s lead program is Gedeptin®, a gene-directed oncolytic therapy for solid tumors. Following a successful multicenter Phase 1/2 trial in advanced head and neck cancers, the Company is planning a follow-on Phase 2 trial evaluating Gedeptin® in combination with an immune checkpoint inhibitor in patients with first recurrent disease. GeoVax holds worldwide rights to its product candidates and underlying technologies, supported by a strong intellectual property portfolio. The Company is led by a proven management team with decades of experience creating value across the life sciences sector.

* The Corporate Snapshot was last updated on April 2, 2025.